• News

Drug Offers Hope Against a Tough-to-Treat Blood Cancer

  • Health Day
  • New York, NY
  • (August 21, 2019)

Patients with a form of blood cancer known as multiple myeloma who haven't responded to other therapies might have a new weapon against the disease, according to researchers at the Icahn School of Medicine at Mount Sinai and published in The New England Journal of Medicine. A drug called selinexor appeared to help patients with the blood and bone marrow cancer, according to a clinical trial involving 122 people. "This study proved that a novel, first-in-class drug with a new mechanism of action can kill a patient's cancer cells," said senior author Sundar Jagannath, MD, director of the myeloma program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. He added, “Selinexor also worked in patients who had exhausted every other treatment and who would have been placed on hospice care otherwise." According to study author Ajai Chari, MD, associate professor, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai, “This study is meaningful for patients with multiple myeloma who haven't had success on multiple other therapies.”

— Sundar Jagannath, MD, Professor, Medicine, Hematology, Medical Oncology, Director, Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai

— Ajai Chari, MD, Director, Clinical Research in the Multiple Myeloma Program, Associate Director, Clinical Research, Mount Sinai Cancer Clinical Trials Office, Associate Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai

Learn more 

Additional coverage: U.S. News & World Report;Medical Xpress;Onclive; Yahoo Finance; Healio: HemOnc Today; Doctors Lounge; Clinical Connection; Science Magazine; eCancer; News-Medical